Canada OKs Pfizer COVID-19 Booster For Kids Aged 5-11 Years - Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX)

Canada's health ministry authorized the use of Pfizer Inc PFE and BioNTech SE's BNTX COVID-19 vaccine as a booster for children 5 - 11 years old at least six months after their initial two doses.-
The 10 mcg dose was authorized, and this is the first COVID-19 vaccine authorized as a booster dose in this age group.
The authorization for a booster shot was granted after a thorough, independent review of the vaccine, which provides "an option to restore their child's protection against COVID-19, especially those at high risk of severe illness," the health ministry wrote on Twitter.
Also Read: Biden Administration To Stop Purchasing COVID-19 Solutions By End Of 2022.
Moderna Inc's MRNA COVID-19 vaccine is authorized only as a primary series for children 6 - 11 years of age, using a 50 mcg dose, and for children six months to 5 years of age, using a 25 mcg dose.
Booster doses of Moderna Spikevax (50 mcg) COVID-19 vaccine are authorized only for individuals 18 and older.
In moderate to severely immunocompromised children, the Canadian authority recommends a primary series of three doses administered at least 4 to 8 weeks apart for both mRNA vaccines.
Price Action: BNTX shares closed at $147.92, and PFE stock closed at $49.15 on Friday.